EcoDrugPlus

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSHCOG00000000235
Gene Symbol: LOC109519047
3 Cross references
208 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSHCOG00000008146
Gene Symbol: MAPKAPK2
3 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSHCOG00000005302
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSHCOG00000012125
Gene Symbol: MCL1B
1 Cross references
209 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSHCOG00000004090
Gene Symbol: MDM2
3 Cross references
278 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSHCOG00000016015
Gene Symbol: MET
3 Cross references
202 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSHCOG00000000070
Gene Symbol: MLST8
3 Cross references
198 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSHCOG00000014787
Gene Symbol: NOX4
4 Cross references
151 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSHCOG00000016412
Gene Symbol: NPC1L1
4 Cross references
189 Possible Orthologues:

Nt-3 Growth Factor Receptor-Like

Ensembl ID : ENSHCOG00000007482
Gene Symbol: LOC109513079
2 Cross references
202 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSHCOG00000001522
Gene Symbol: LOC109521671
3 Cross references
197 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSHCOG00000009885
Gene Symbol: LOC109524401
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).